Relay Therapeutics Reports Interim Data for Breast Cancer Treatment
Relay Therapeutics Reports Interim Data for Breast Cancer Treatment
Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced positive interim data for RLY-2608, the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα. The data showed that despite heavy pre-treatment, patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer who received RLY-2608 600mg BID + fulvestrant demonstrated clinically meaningful progression free survival (PFS).
Relay Therapeutics, Inc.（纳斯达克股票代码：RLAY）是一家临床阶段的精准医疗公司，通过结合尖端的计算和实验技术来改变药物发现过程。该公司今天公布了PI3Kα的首个已知在研变构、泛突变体和异形选择性抑制剂 RLY-2608 的积极中期数据。数据显示，尽管进行了大量的预治疗，但接受了 RLY-2608 600mg BID + fulvestrant 的 PI3Kα突变、HR+、HER2-局部晚期或转移性乳腺癌患者表现出具有临床意义的无进展存活率（PFS）。
